Investigation of biological significance of neutral amino acid transporter expression in human brain tumors and development of novel therapeutic strategies
人脑肿瘤中中性氨基酸转运蛋白表达的生物学意义的研究和新治疗策略的开发
基本信息
- 批准号:15591547
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Objectives. Malignant tumor cells show an elevated proliferative activity which would require increased intracellular metabolism. LAT1, in the presence of its co-factor 4F2hc, constitutes the system L neurtral amino acid transporter which is responsible for cellular transport of most essential amino acids. Recent reports demonstrating increased expression of LAT1 in cancer cells prompted us to investigate its expression and biological roles in human glioma cells.Methods. Expression of LAT1 and 4F2hc was determined in 13 human glioma cell lines using Western blot and RT-PCR analyses. LAT1-positive glioma cells were treated with a system L inhibitor BCH, and their proliferation and apoptosis rates were examined by BrdU staining and TUNEL assay, respectively. LAT1-negative glioma cells were transfected with the plasmid encoding human LAT1 cDNA and the cells expressing high levels of LAT1 were subjected to in vitro growth assays, and were injected into nude mice subcutaneously as well. Ami … More no acid uptake activity was measured using ^<14>C-Leu.Results. Majority of glioma cell lines expressed LAT1 protein. All cell lines were positive for 4F2hc mRNA expression. BCH treatment resulted in significant reduction of proliferation in LAT1-positive LNZ308 cells, whereas it was ineffective in LAT1-negative LN319 cells. LNZ308 cells showed reduced proliferation and increased apoptosis upon BCH treatment, which were accompanied with changes of expression levels of cell-cycle regulators and caspase activation. Introduction of LAT1 did not affect growth rates in LN319 cells in vitro. However, LAT1 overexpression leading to 3.4-fold increase in amino acid uptake activity in U87MG cells resulted in enhanced tumorigenicity in vivo.Conclusions. LAT1 and its partner 4F2hc are expressed in majority of human glioma cells. Our results suggest that LAT1, the major component of the amino acid transport system, may play an important role in gliomagenesis and may be a novel potential therapeutic target for malignant gliomas. Less
目标.恶性肿瘤细胞显示出升高的增殖活性,这将需要增加的细胞内代谢。LAT 1在其辅因子4F 2 hc的存在下,构成负责大多数必需氨基酸的细胞转运的系统L神经质氨基酸转运蛋白。最近的研究表明LAT 1在肿瘤细胞中的表达增加,这促使我们研究其在人脑胶质瘤细胞中的表达和生物学作用。采用Western blot和RT-PCR方法检测了13株人脑胶质瘤细胞系中LAT 1和4F 2 hc的表达。用L系统抑制剂BCH处理LAT 1阳性胶质瘤细胞,分别用BrdU染色和TUNEL法检测其增殖和凋亡率。用编码人LAT 1 cDNA的质粒转染LAT 1阴性胶质瘤细胞,并对表达高水平LAT 1的细胞进行体外生长测定,并将其皮下注射到裸鼠中。AMI ...更多信息 使用14 C-Leu没有测量酸摄取活性<14>。大多数胶质瘤细胞系表达LAT 1蛋白。所有细胞系4F 2 hc mRNA表达均为阳性。BCH处理导致LAT 1阳性LNZ 308细胞的增殖显著降低,而在LAT 1阴性LN 319细胞中无效。BCH处理后LNZ 308细胞增殖下降,凋亡增加,细胞周期调控因子表达水平和caspase活性发生变化。LAT 1的引入并不影响LN 319细胞在体外的生长速率。然而,LAT 1过表达导致U87 MG细胞中氨基酸摄取活性增加3.4倍,导致体内致瘤性增强。LAT 1及其配偶体4F 2 hc在大多数人脑胶质瘤细胞中表达。我们的研究结果表明,LAT 1,氨基酸转运系统的主要组成部分,可能在胶质瘤的发生中发挥重要作用,并可能是一个新的潜在的恶性胶质瘤的治疗靶点。少
项目成果
期刊论文数量(52)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Meningeal Melanocytoma Associated with Ipsilateral Nevus of Ota Presenting Intracerebral Hemorrhage. A case report.
脑膜黑色素细胞瘤与同侧太田痣相关,表现为脑出血。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Hino K;Nagane M;Fujioka Y;Shiokawa Y.
- 通讯作者:Shiokawa Y.
Randomized Controlled Trial on Malignant Brain Tumors-Activities of the Jaan Clinical Oncology Group-Brain Tumor Study Group
恶性脑肿瘤随机对照试验 - Jaan 临床肿瘤学组 - 脑肿瘤研究组的活动
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:Shibui S;Japan Clinical Oncology Group-Brain Tumor Study Group
- 通讯作者:Japan Clinical Oncology Group-Brain Tumor Study Group
The 4th line-chemotherapy with doxorubicin in a patient with recurrent gliosarcoma ; A case report(in Japanese)
第四线——阿霉素化疗治疗复发性胶质肉瘤患者;
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Ohnishi A;Nagane M et al.
- 通讯作者:Nagane M et al.
脳腫瘍の分子生物学.脳腫瘍I,脳神経外科学大系6,第1版,山浦晶編
脑肿瘤分子生物学。脑肿瘤 I,神经外科 6,第 1 版,山浦晃编辑
- DOI:
- 发表时间:2004
- 期刊:
- 影响因子:0
- 作者:大西晶子;永根基雄;他;永根基雄
- 通讯作者:永根基雄
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAGANE Motoo其他文献
NAGANE Motoo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAGANE Motoo', 18)}}的其他基金
Development of novel combined therapies with anti-EGFR monoclonal antibody and anticancer drug for malignant gliomas
抗EGFR单克隆抗体与抗癌药物联合治疗恶性胶质瘤的新型疗法的开发
- 批准号:
22591618 - 财政年份:2010
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel therapeutic strategy by inhibition of multiple signal transduction pathways for malignant gliomas
通过抑制多种信号转导途径治疗恶性胶质瘤的新策略
- 批准号:
19591701 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of therapeutic activity of fully human anti-human TRAIL receptor monoclonal antibodies against malignant glioma
全人源抗人TRAIL受体单克隆抗体对恶性胶质瘤的治疗活性研究
- 批准号:
17591529 - 财政年份:2005
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigation of molecular mechanisms of cell death induced by combination treatment with TRAIL and chemotherapy in malignant gliomas
TRAIL联合化疗诱导恶性胶质瘤细胞死亡的分子机制研究
- 批准号:
13671463 - 财政年份:2001
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Targeting the Amino Acid Transporter SLC7A5 for Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
- 批准号:
10630480 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Determinants of amino acid transporter oligomerization in membranes
膜中氨基酸转运蛋白寡聚的决定因素
- 批准号:
10725968 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
氨基酸转运蛋白 SLC38A5 作为 TNBC 的药物靶点:用遗传和药理学方法进行评估
- 批准号:
10576760 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Targeting the Amino Acid Transporter SLC7A5 for Treatment of Pulmonary Fibrosis
靶向氨基酸转运蛋白 SLC7A5 治疗肺纤维化
- 批准号:
10683793 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Structural and functional elucidation of L-type amino acid transporter under lipid environment
脂质环境下L型氨基酸转运蛋白的结构和功能阐明
- 批准号:
21K15031 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of new BNCT sensitizer based on molecular chirality recognition of amino acid transporter LAT
基于氨基酸转运蛋白LAT的分子手性识别开发新型BNCT敏化剂
- 批准号:
21K19348 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Elucidation of tissue-repair response in lung fibrosis by focusing on the amino acid transporter SLC15A3
通过关注氨基酸转运蛋白 SLC15A3 阐明肺纤维化中的组织修复反应
- 批准号:
21K16155 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Hybridized structure- and ligand- based drug discovery approaches targeting ASCT2, an amino acid transporter critical for upregulated cell proliferation in numerous cancer types
针对 ASCT2 的基于杂交结构和配体的药物发现方法,ASCT2 是一种氨基酸转运蛋白,对于多种癌症类型的细胞增殖上调至关重要
- 批准号:
10333203 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Exploration of new therapeutic strategy targeting amino acid transporter in renal cell carcinoma
肾细胞癌靶向氨基酸转运蛋白治疗新策略的探索
- 批准号:
20K18108 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigating the Physiological Role of Cl- permeation through Excitatory Amino Acid Transporter 1 (
通过兴奋性氨基酸转运蛋白 1 研究氯渗透的生理作用(
- 批准号:
552252-2020 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
University Undergraduate Student Research Awards